| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
B and IFN Regulatory Factor 1 Activation1
*
Department of Biological Sciences, Rutgers University, Newark, NJ 07102; and
Departamento Biologia Celular, Universidad Complutense, 28040 Madrid, Spain
High-output nitric oxide (NO) production from activated
macrophages, resulting from the induction of inducible NO synthase
(iNOS) expression, represents a major mechanism for macrophage
cytotoxicity against pathogens. However, despite its beneficial role in
host defense, sustained high-output NO production was also implicated
in a variety of acute inflammatory diseases and autoimmune diseases.
Therefore, the down-regulation of iNOS expression during an
inflammatory process plays a significant physiological role. This study
examines the role of two immunomodulatory neuropeptides, the vasoactive
intestinal peptide (VIP) and the pituitary adenylate cyclase-activating
polypeptide (PACAP), on NO production by LPS-, IFN-
-, and
LPS/IFN--stimulated peritoneal macrophages and the Raw 264.7 cell
line. Both VIP and PACAP inhibit NO production in a dose- and
time-dependent manner by reducing iNOS expression at protein and mRNA
level. VPAC1, the type 1 VIP receptor, which is constitutively
expressed in macrophages, and to a lesser degree VPAC2, the type 2 VIP
receptor, which is induced upon macrophage activation, mediate the
effect of VIP/PACAP. VIP/PACAP inhibit iNOS expression and activity
both in vivo and in vitro. Two transduction pathways appear to be
involved, a cAMP-dependent pathway that preferentially inhibits IFN
regulatory factor-1 transactivation and a cAMP-independent pathway that
blocks NF-
B binding to the iNOS promoter. The down-regulation of
iNOS expression, together with previously reported inhibitory effects
on the production of the proinflammatory cytokines IL-6, TNF-
, and
IL-12, and the stimulation of the anti-inflammatory IL-10, define
VIP and PACAP as "macrophage deactivating factors" with significant
physiological relevance.
This article has been cited by other articles:
|
|
 |
|
  L. Lajavardi, A. Bochot, S. Camelo, B. Goldenberg, M.-C. Naud, F. Behar-Cohen, E. Fattal, and Y. de Kozak Downregulation of Endotoxin-Induced Uveitis by Intravitreal Injection of Vasoactive Intestinal Peptide Encapsulated in Liposomes Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3230 - 3238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Szliter, S. Lighvani, R. P. Barrett, and L. D. Hazlett Vasoactive Intestinal Peptide Balances Pro- and Anti-Inflammatory Cytokines in the Pseudomonas aeruginosa-Infected Cornea and Protects against Corneal Perforation J. Immunol., January 15, 2007; 178(2): 1105 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D'Angelo, M. Pecchiari, P. D. Valle, A. Koutsoukou, and J. Milic-Emili Effects of mechanical ventilation at low lung volume on respiratory mechanics and nitric oxide exhalation in normal rabbits J Appl Physiol, August 1, 2005; 99(2): 433 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Martinez, Y. Juarranz, C. Abad, A. Arranz, B. G. Miguel, F. Rosignoli, J. Leceta, and R. P. Gomariz Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock J. Leukoc. Biol., May 1, 2005; 77(5): 729 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kato, A. Ito, J. Kawanokuchi, S. Jin, T. Mizuno, K. Ojika, R. Ueda, and A. Suzumura Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells Multiple Sclerosis, December 1, 2004; 10(6): 651 - 659. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Delgado Inhibition of Interferon (IFN) {gamma}-induced Jak-STAT1 Activation in Microglia by Vasoactive Intestinal Peptide: INHIBITORY EFFECT ON CD40, IFN-INDUCED PROTEIN-10, AND INDUCIBLE NITRIC-OXIDE SYNTHASE EXPRESSION J. Biol. Chem., July 18, 2003; 278(30): 27620 - 27629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-W. Chen, Y.-H. Chang, C.-J. Tsi, and W.-W. Lin Inhibition of IFN-{gamma}-Mediated Inducible Nitric Oxide Synthase Induction by the Peroxisome Proliferator-Activated Receptor {gamma} Agonist, 15-Deoxy-{Delta}12,14-Prostaglandin J2, Involves Inhibition of the Upstream Janus Kinase/STAT1 Signaling Pathway J. Immunol., July 15, 2003; 171(2): 979 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Macdonald, H. F. Galley, and N. R. Webster Oxidative stress and gene expression in sepsis Br. J. Anaesth., February 1, 2003; 90(2): 221 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado, J. Leceta, and D. Ganea Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia J. Leukoc. Biol., January 1, 2003; 73(1): 155 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Gu, R. Y. Lee, T. C. Skaar, K. B. Bouker, J. N. Welch, J. Lu, A. Liu, Y. Zhu, N. Davis, F. Leonessa, et al. Association of Interferon Regulatory Factor-1, Nucleophosmin, Nuclear Factor-{kappa}B, and Cyclic AMP Response Element Binding with Acquired Resistance to Faslodex (ICI 182,780) Cancer Res., June 1, 2002; 62(12): 3428 - 3437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ganea and M. Delgado VASOACTIVE INTESTINAL PEPTIDE (VIP) AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AS MODULATORS OF BOTH INNATE AND ADAPTIVE IMMUNITY Critical Reviews in Oral Biology & Medicine, May 1, 2002; 13(3): 229 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Abad, C. Martinez, J. Leceta, R. P. Gomariz, and M. Delgado Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Collagen-Induced Arthritis: An Experimental Immunomodulatory Therapy J. Immunol., September 15, 2001; 167(6): 3182 - 3189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado and D. Ganea Inhibition of Endotoxin-Induced Macrophage Chemokine Production by Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide In Vitro and In Vivo J. Immunol., July 15, 2001; 167(2): 966 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ikegami, Y. Sugimoto, E. Segi, M. Katsuyama, H. Karahashi, F. Amano, T. Maruyama, H. Yamane, S. Tsuchiya, and A. Ichikawa The Expression of Prostaglandin E Receptors EP2 and EP4 and Their Different Regulation by Lipopolysaccharide in C3H/HeN Peritoneal Macrophages J. Immunol., April 1, 2001; 166(7): 4689 - 4696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Lara-Marquez, M. S. O'Dorisio, T. M. O'Dorisio, M. H. Shah, and B. Karacay Selective Gene Expression and Activation-Dependent Regulation of Vasoactive Intestinal Peptide Receptor Type 1 and Type 2 in Human T Cells J. Immunol., February 15, 2001; 166(4): 2522 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado and D. Ganea Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Expression of Fas Ligand in Activated T Lymphocytes by Regulating c-Myc, NF-{{kappa}}B, NF-AT, and Early Growth Factors 2/3 J. Immunol., January 15, 2001; 166(2): 1028 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado and D. Ganea Inhibition of IFN-{gamma}-Induced Janus Kinase-1-STAT1 Activation in Macrophages by Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide J. Immunol., September 15, 2000; 165(6): 3051 - 3057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vaudry, B. J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions Pharmacol. Rev., June 1, 2000; 52(2): 269 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-K. Kim, Y. Kan, D. Ganea, R. P. Hart, I. Gozes, and G. M. Jonakait Vasoactive Intestinal Peptide and Pituitary Adenylyl Cyclase-Activating Polypeptide Inhibit Tumor Necrosis Factor-alpha Production in Injured Spinal Cord and in Activated Microglia via a cAMP-Dependent Pathway J. Neurosci., May 15, 2000; 20(10): 3622 - 3630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Fournier, V. Atger, J.-L. Paul, M. Sturm, N. Duverger, G. H. Rothblat, and N. Moatti Human ApoA-IV Overexpression in Transgenic Mice Induces cAMP-Stimulated Cholesterol Efflux From J774 Macrophages to Whole Serum Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1283 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado and D. Ganea Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Interleukin-12 Transcription by Regulating Nuclear Factor kappa B and Ets Activation J. Biol. Chem., November 5, 1999; 274(45): 31930 - 31940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado, W. Sun, J. Leceta, and D. Ganea VIP and PACAP Differentially Regulate the Costimulatory Activity of Resting and Activated Macrophages Through the Modulation of B7.1 and B7.2 Expression J. Immunol., October 15, 1999; 163(8): 4213 - 4223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado and D. Ganea Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Nuclear Factor-kappa B-dependent Gene Activation at Multiple Levels in the Human Monocytic Cell Line THP-1 J. Biol. Chem., January 5, 2001; 276(1): 369 - 380. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
